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Abstract
Background: Up to 80% of patients dying from prostate carcinoma have developed bone metastases that are
incurable. Castration is commonly used to treat prostate cancer. Although the disease initially responds to androgen
blockade strategies, it often becomes castration-resistant (CRPC for Castration Resistant Prostate Cancer). Most of
the murine models of mixed lesions derived from prostate cancer cells are androgen sensitive. Thus, we established
a new model of CRPC (androgen receptor (AR) negative) that causes mixed lesions in bone.
Methods: PC3 and its derived new cell clone PC3c cells were directly injected into the tibiae of SCID male mice.
Tumor growth was analyzed by radiography and histology. Direct effects of conditioned medium of both cell lines
were tested on osteoclasts, osteoblasts and osteocytes.
Results: We found that PC3c cells induced mixed lesions 10 weeks after intratibial injection. In vitro, PC3c
conditioned medium was able to stimulate tartrate resistant acid phosphatase (TRAP)-positive osteoclasts.
Osteoprotegerin (OPG) and endothelin-1 (ET1) were highly expressed by PC3c while dikkopf-1 (DKK1) expression
was decreased. Finally, PC3c highly expressed bone associated markers osteopontin (OPN), Runx2, alkaline
phosphatase (ALP), bone sialoprotein (BSP) and produced mineralized matrix in vitro in osteogenic conditions.
Conclusions: We have established a new CRPC cell line as a useful system for modeling human metastatic
prostate cancer which presents the mixed phenotype of bone metastases that is commonly observed in prostate
cancer patients with advanced disease. This model will help to understand androgen-independent mechanisms
involved in the progression of prostate cancer in bone and provides a preclinical model for testing the effects of new
treatments for bone metastases.
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Introduction
Bone is the most frequent site of prostate carcinoma
metastases with bone metastases in up to 80% of advanced
disease [1]. Surgical and hormonal therapies have shown
beneficial effects only for early-stage hormone-responsive
disease. Indeed, if the disease in most cases initially responds,
it often progresses and become androgen independent. At that
stage, patients with advanced disease often display
osteoblastic or mixed lesions in bone [2,3]. The mechanisms by
which prostate cancers are induced to metastasize to bone rely
on a complex interplay between prostate cancer cells and the
bone microenvironment [4]. Growth of prostate cancer cells
alters bone remodeling (formation and resorption) by secreting
factors that will directly affect osteoblasts (bone forming cells)
and osteoclasts (bone resorbing cells). RANKL (Receptor
activator of NF-kB ligand) stimulates osteoclasts differentiation
and action while osteoprotegerin (OPG) acts as a decoy
receptor for RANK (RANKL receptor). Therefore the balance
between RANKL and OPG, that can be both produced by
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prostate cancer cells, is critical in controlling osteoclast activity
and osteolysis in bone metastasis [4-6]. On the other side, pro-
osteoblastic molecules can also be produced by prostate
cancer cells. In fact, the first clinical studies to specifically
target osteoblasts in patients with metastatic prostate cancer
was based on endothelin-1 (ET1), a mitogenic factor for
osteoblasts that can promote the growth of osteoblasts at
metastatic sites [7,8]. In addition, transforming growth factor β
(TGFβ), vascular endothelial growth factor (VEGF) are
abundantly expressed by the prostate cancer cells and have a
direct effect on osteoblast function [9,10]. The wingless (WNT)
pathway that is implicated in osteoblastogenesis has been also
implicated in the development of osteoblastic metastasis in
prostate cancer [11]. Up-regulation of the WNT-family ligand
WNT1 in prostate cancer cells and a decrease in the serum of
the WNT antagonist dikkopf-1 (DKK1) expression has been
reported in patients with advanced metastatic prostate
carcinoma and is associated with osteoblastic lesions [12].
Finally prostate cancer cells that induce bone metastasis also
express large amount of bone associated factors like
osteopontin (OPN), osteocalcin (OCN) or bone sialoprotein
(BSP) secreted in the bone matrix and that will contribute to
promote their osteomimicry properties [13].
The majority of mixed bone metastases derived from
prostate cancer mouse models are androgen sensitive and for
that matter do not really mimic the clinical situation. We
described the characterization of a new cell line (namely PC3c)
that induce mixed skeletal lesions in animals that is derived
from the human androgen independent AR-negative cell line
PC3, known to induce pure osteolytic bone metastases.
Materials and Methods
Ethics statement
The mice used in our study were handled according to the
rules of Décret N° 87-848 du 19/10/1987, Paris. The
experimental protocol have been reviewed and approved by
the Rhone-Alpes Regional Committee on the Ethic of Animal
Experiments (Lyon, France) (Register Number: 0121). Animal
experiments were routinely inspected by the attending
veterinarian to ensure continued compliance with the proposed
protocols. SCID mice, 6 weeks age, were housed under barrier
conditions in laminar flow isolated hoods. Animals bearing
tumor xenografts were carefully monitored for established signs
of distress and discomfort and were humanely euthanized.
Cell culture
PC3 cell line was obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). The PC3c cells, a
subculture cell line of PC3 was isolated in our laboratory in vitro
after single cell population culture. Consequently to
spontaneous derivation of the cells, we finally obtained a
subculture cell line named PC3c which was chosen based on
its epithelial phenotype (Figure S1) [14,15]. The hormone
dependent human prostate cancer VCAP cells were a
generous gift of Pr M Cecchini (Department of Clinical
Research, University of Bern, Bern, Switzerland) and was
obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA). VCAP were cultured in RPMI medium.
PC3 and PC3c cells were routinely cultured in F12K nutrient
mixture and DMEM medium (Life technologies, Carlsbad, CA,
USA) respectively supplemented with 10% (v/v) fetal bovine
serum (FBS; Perbio/Thermo scientific; Rockford, IL, USA) and
1% (v/v) penicillin/streptomycin (Life technologies, Carlsbad,
CA, USA) at 37°C in a 5% CO2 incubator. PC3 and PC3c were
also cultured upon osteogenic conditions for three weeks in the
osteoblast medium supplemented with 50 µg/ml ascorbic acid
(Sigma-Aldrich, Buchs, Switzerland). Ten mM sodium β-
glycerophosphate (Sigma-Aldrich, Buchs, Switzerland) was
added during 1 week at the end of the culture. PC3 and PC3c
were continuously (day 1 to day 21) exposed to osteogenic
conditions. For the visualization of mineralization, wells were
fixed and stained with von Kossa and for ALP [16].
Animal studies
For intra-osseous tumor xenograft experiments (Charles
River Laboratories, Wilmington, MA, USA), a small hole was
drilled with a 26-gauge sterile needle through the right tibia with
the knee flexed in anesthetized 6- to 8-week-old SCID mice.
Using a new sterile needle fitted to a 50-µl sterile Hamilton
syringe (Hamilton Co.; Bonaduz, GR, Switzerland), a single-cell
suspension (6x105 in 15-µl PBS) of PC3 or PC3c cells was
carefully injected in the bone marrow cavity. From week 2 after
tumor cell inoculation, radiographs of anesthetized mice were
weekly taken with the use of MIN-R2000 films (Kodak,
Rochester, NY, USA) in an MX-20 cabinet X-ray system
(Faxitron X-ray Corp, Tucson, AZ, USA). Animals were
euthanized after 6 and 10 weeks for mice injected by PC3 and
PC3c cells respectively. Microcomputed tomography analyses
were carried out using a micro-CT scanner Skyscan 1174
(Skyscan; Kontich, Belgium). The X-ray tube was set to a
voltage of 50 kV and a current of 800 µA. A 0.5 mm aluminum
filter was used to reduce beam hardening artifacts. Samples
were scanned in 70% ethanol with a voxel size of 20 µm. For
each sample, 265 section images were reconstructed with
NRecon software (version 1.6.1.8, Skyscan). Three-
dimensional modeling and analysis of BV (Bone Volume)/TV
(Total Volume) ratio (percentage of bone tissue) were obtained
with the CTAn (version 1.9, Skyscan) and CTVol (version 2.0,
Skyscan) software. The dissected bones were then processed
for histological and histomorphometric analysis.
Subcutaneous injections of PC3c cells (106 in 100µl PBS)
were also performed in 6- to 8-week-old SCID mice. Animals
were euthanized after 12 weeks and tumors were fixed and
embedded in paraffin.
Bone histomorphometry and histology
Tibia from animals were fixed, decalcified with 15% EDTA/
0,4% PFA and embedded in paraffin. Five µm sections were
stained with Goldner’s Trichrome and proceeded for
histomorphometric analyses to calculate the TB (Tumor
Burden)/STV (Soft Tissue Volume) ratio (percentage of tumor
tissue). The in situ detection of osteoclasts was carried out on
metastatic bone tissue sections using the tartrate-resistant acid
phosphatase (TRAP) activity kit assay (Sigma-Aldrich, Buchs,
Switzerland).
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Osteoclastogenesis assay
Primary bone marrow cells were obtained after tibia and
femur bone marrow flushing from 6-week-old OF1 male mice.
Cells were then cultured for 7 days, in differentiation medium:
α-MEM medium containing 10% fetal calf serum (Life
technologies, Carlsbad, CA, USA), 20 ng/mL of M-CSF (R&D
Systems, Minneapolis, MN, USA) and 200 ng/mL of soluble
recombinant RANK-L in presence or absence of conditioned
medium extracted from PC3 and PC3c (25µg of proteins for
each conditions) [17]. Medium was, first, changed every two
days then from day 4 every days. After 7 days, mature
multinucleated osteoclasts (OCs) were obtained and stained
for TRAP activity (Sigma-Aldrich, Buchs, Switzerland),
following the manufacturer’s instructions. Multinucleated TRAP-
positive cells containing three or more nuclei were counted as
OCs.
Osteoblastogenesis assay
Calvaria of 3-day-old OF-1 mice were dissected then cells
were enzymatically isolated by sequential digestion with
collagenase, as described previously [18,19]. Cells obtained
from the last four of the five digestion steps (populations II-V)
were plated onto 24-well plates at 2x104 cells / well. After 24
hours incubation, the medium including α-MEM medium
containing 10% fetal bovine serum (Life technologies,
Carlsbad, CA, USA) was changed and supplemented with
50µg/ml ascorbic acid (Sigma-Aldrich, Buchs, Switzerland) and
with or without conditioned medium (25µg of proteins for each
conditions) extracted from PC3 and PC3c. Medium was
changed every two days for 15 days. 10mM sodium β-
glycerophosphate (Sigma-Aldrich, Buchs, Switzerland) was
added during 1 week at the end of the culture. At day 15, when
bone mineralized nodules were formed, cells were then fixed
and stained with von Kossa for quantification. ALP+ and bone
mineralized nodules were then counted on a grid [16]. Results
are plotted as the mean number of nodules ± SD of three wells
for controls and each condition (PC3, PC3c) and were
representative of two independent experiments. Osteocyte cell
line MLO-Y4 were a generous gift of Pr L Bonewald (School of
Dentistry, University of Missouri, Kansas City, MO, USA) and
were cultured as described previously [20].
Immunocytochemistry
PC3c tumors and metastatic tibia were fixed and embedded
in paraffin. Five µm sections were subjected to
immunohistochemistry using rabbit polyclonal antibodies anti
human/ mouse osteopontin antibody (Bachem, Bubendorf,
Switzerland), anti human Endothelin-1 antibody (Abbiotec, San
Diego, CA, USA) and anti human OPG antibody (Abbiotec, San
Diego, CA, USA). BSP antibody was a generous gift of Dr L
Malaval (University of J Monnet, St Etienne, France). Sections
were deparaffinized in methylcyclohexan, hydrated then treated
with a peroxidase blocking reagent (Dako, Glostrup, Denmark).
Sections were incubated with normal calf serum for 1 hour and
incubated overnight at 4°C with primary antibodies (dilution:
1/100). Sections were incubated with secondary antibody HRP-
conjugated donkey anti rabbit (Amersham/GE Healthcare;
Chalfont St Giles, UK) (dilution 1/300) for 1 hour. After
washing, the sections were revealed by 3,3’-diaminobenzidine
(Dako, Glostrup, Denmark). Counterstaining was performed
using Mayer’s hematoxylin (Merck, Whitehouse Station, NJ,
USA).
Real time RT-PCR
Total RNA was extracted with Trizol reagent (Life
Technologies, Carlsbad, CA, USA) from PC3, PC3c, OBs, OCs
and MLO-Y4 cells. Samples of total RNA (1 µg) were reverse-
transcribed using random hexamer (Promega, Madison, WI,
USA) and the first strand synthesis kit of SuperscriptTM II (Life
Technologies, Carlsbad, CA, USA). Real-time RT-PCR was
performed on a Roche Lightcycler Module (Roche, Penzberg,
Germany) with primers specific for human and mouse (see
Tables S1 and S2). Real-time RT-PCR was carried out by
using SYBR Green (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions with an initial step for 10 min at
95°C followed by 40 cycles of 20 sec at 95°C, 10 sec at Tm
(see Tables S1 and S2) and 10 sec at 72°C. We verified that a
single peak was obtained for each product using the
Lightcycler Roche software. Amplimers were all normalized to
corresponding L32 values. Data analysis was carried out using
the comparative CT method: in real-time each replicate
average genes CT was normalized to the average CT of L32
by subtracting the average CT of L32 from each replicate to
give the ∆CT. Results are expressed as Log-2 __CT with ∆∆CT
equivalent to the ∆CT of the genes in PC3, PC3c or treated
OBs, OCs and MLO-Y4 cells subtracting to the ∆CT of the
endogenous control (non-treated OBs, OCs and MLO-Y4 cells
respectively).
Electron microscopy
PC3c cells were cultured on glass coverslips, then fixed for
1h in 2% glutaraldehyde in 0.1M of sodium cacodylate buffer at
pH7.4. After three rinses in 0.2M saccharose in 0.1M of sodium
cacodylate buffer, the cells were postfixed in 1% osmium
tetroxyde in 0.15M cacodylate buffer, dehydrated in graded
ethanol, then embedded in Epon. Ultrathin sections were
counterstained with uranyl acetate and lead citrate, the
examined under a 1200 EX JEOL electron microscope (Jeol,
Tokyo, Japan).
Fourier Transform InfraRed Microspectroscopy (FTIRM)
Undecalcified sections (2µm-thick) of tibia embedded in
MMA were cut longitudinally with a microtome Polycut
(Reichert-Jung, Leica, Germany), and stored between 2 glass
slides. FTIRM was performed with a PerkinElmer GXII Auto-
image Microscope (Norwalk, CT, USA), equipped with a cooled
liquid nitrogen wide band Mercury Cadmium Telluride detector
(7800-400 cm-1). Infrared measurements were performed on
bone matrix (in cortical bone) around the tumor and on the
tumor itself. Infrared measurement of cortical bone from sham
mice was also collected. IR spectra were collected in
transmission mode, at 4 cm-1 of spatial resolution, and 40 µm X
40 µm of spatial resolution. Contribution of air and MMA were
subtracted from the original spectrum. Automatic baseline
correction was performed on each IR spectrum with Spectrum
software (PerkinElmer, Inc).
New Androgen-Resistant Bone Metastasis Model
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Statistical analysis
Data were expressed as mean +/- SD, and analyzed
statistically by one way analysis of variance (ANOVA) followed
by post hoc t-tests or student t-test to assess the differences
between groups for in vitro and in vivo studies. Statistical
significance was taken as p<0.05.
Results
Expression of pro-osteoblastic factors by PC3c cells
From human androgen-resistant prostate cancer cell line
PC3, we obtained after single cell population culture in vitro a
new subculture cell line named PC3c cells that was chosen
based on its epithelial phenotype (Figure S1). As expected and
similarly to the parental PC3 cells, AR could not be detected by
real-time PCR in PC3c while it was expressed in the hormone
dependant cell line VCaP used as a positive control (Figure
1A). On the other hand, the prostate markers P504S (alpha
methylacyl-coA racemase (AMACR)) and the prostatic acid
phosphatase (PAP) were expressed in both cell lines
confirming the prostate origin of the cells (Figure 1B) [21].
Characterization by real-time PCR of PC3c cells indicated
that ET1 and OPG, two factors that have been implicated in the
pathogenesis of osteosclerotic bone metastases from prostate
cancer are overexpressed compared to the parental cell line
PC3 (Figure 1C-D) while other factors such as fibroblast growth
Figure 1.  Expression of pro-osteoblastic factors by PC3c cells.  Detection by real-time PCR of AR mRNA expression in PC3,
PC3c and VCAP cancer cells lines (A), AMACR, PAP (B) and DKK1, ET-1, FGF9, Noggin, OPN, OPG, Runx2 and TGFβ mRNA
expression (C and D) in PC3 and PC3c cancer cells lines. Genes expression was assessed by real-time PCR on triplicate samples
and normalized against that of the ribosomal protein gene L32 *p<0.05; **p<0,001, ***p<0,0001.
doi: 10.1371/journal.pone.0075092.g001
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factor 9 (FGF9) and TGFβ are similarly expressed in both cell
lines [8,22,23]. On the other hand, the expression of DKK1 and
Noggin, two osteoblast inhibitors (respectively Wnts and bone
morphogenetic protein (BMP) inhibitors), is decreased in PC3c
versus PC3 (Figure 1 C-D) [24,25]. Moreover, PC3c similarly to
PC3 cells expressed factors known to be implicated in prostate
cancer osteomimicry such as OPN and Runx2. All together,
these results suggest that PC3c cells may potentially induce
osteoblastic lesions when compared with PC3 cells that are
known to predominantly exhibit osteolytic lesions in bone.
PC3c cells induce mixed osteoblastic/osteolytic bone
lesions
In order to test the property of PC3c to induce bone lesions,
intra-tibial injections were performed into male SCID mice. Ten
weeks after tumor cell inoculation, radiographic analysis
revealed that animals bearing PC3c tumors had bone lesions
that included osteolytic and osteoblastic components (Figure
2I) while pure osteolytic lesions were observed in animal
bearing PC3 tumors after 6 weeks (Figure 2E). The capacity of
PC3 and PC3c to induce pure osteolytic and mixed lesions,
respectively, was confirmed using 3D micro-CT reconstruction
(Figure 2F-G and J-K) (bone volume, BV/TV, Table 1),
histology (Figure 2H and L) and histomorphometric analyses of
tibiae (skeletal tumor burden, TB/STV; Table 1). As expected
no skeletal lesions were observed after PBS injection (Sham
animals) (Figure 2A-D, Table 1). By immunohistochemistry, we
confirmed, in vivo, that ET-1 and OPG were highly expressed
in PC3c tumors (Figure S1, B, D) when compared with PC3
(Figure S2, A, C).
Bone remodeling stimulation by PC3c cells
Given these data, we next asked whether PC3c could alter
the bone resorbing cells, the osteoclasts (OCs) and the bone
forming cells, the osteoblasts (OBs). Treatment of primary
mouse bone marrow cells with RANKL, macrophage colony
stimulating factor (M-CSF) and with the conditioned medium of
PC3c stimulated more the formation of tartrate resistant acid
phosphatase (TRAP)-positive multinucleated OCs compared
with that observed with the conditioned medium of PC3 cells
and untreated cells (Ct) (Figure 3A). On the other side,
treatment of primary mouse calvaria cells cultured in
osteogenic conditions with the conditioned medium of PC3c
had less inhibitory effect on OB differentiation than conditioned
medium of PC3 cells compared with untreated cells (Ct)
(Figure 3B). Indeed, a high number of OBs was visualized
using OPN immunostaining in vivo (Figure 4A a-b).
Interestingly, PC3 conditioned medium stimulated OPG and
RANKL expression by primary OBs while PC3c conditioned
medium decreased OPG production leading to a stronger
increase of RANKL/OPG ratio by OBs treated with PC3c
conditioned medium compared with that of PC3 cells (Figure
3C). Consistent with these in vitro results, TRAP staining of
tibial sections of metastatic legs from animals bearing PC3c
showed high number of TRAP-positive multinucleated OCs
compared with that observed in PC3 and Sham animals
(Figure S3). Finally, semi-quantitative PCR performed on the
osteocyte cell line, MLO-Y4, allowed us to show that sclerostin
(SOST) and Dentin matrix acidic phosphoprotein 1 (DMP1)
expression was stimulated after 24h of treatment with PC3 and
PC3c conditioned medium respectively while OPG and RANKL
expression was not affected (Figure 3D).
PC3c cells induce robust osteoblastic reactions upon
osteogenic conditions
Because PC3c cells induced new bone formation in vivo, we
next tested whether they could produce OBs markers. After
immunostaining of bone metastatic tissue sections, OPN and
BSP were found expressed in PC3c cells in situ (Figure 4B a
and b). Moreover after 3 weeks of culture, in vitro, upon
osteogenic conditions including ascorbic acid and β-
glycerophosphate (Fig 4C b and d), PC3c cells were revealed
to be alkaline phosphatase (ALP)-positive (Fig 4Cc) and were
able to form a calcified matrix positive for von Kossa staining
(Fig 4C d), while PC3 were ALP-negative and did not induce
matrix mineralization (Figure 4C a and b). Expression of ALP
after ascorbic acid treatment was confirmed in PC3c cells by
real-time PCR (Figure 4D). Similarly, OPN was highly
expressed in PC3c compared to PC3 cells while OCN was
expressed by both cells lines under these experimental
conditions (Figure 4D), suggesting high osteomimicry property
of PC3c compared to PC3 cells. Finally, Fourier Transform
InfraRed Microspectroscopy (FTIRM) study on tumors obtained
after subcutaneous injection of PC3c cells revealed the
presence of amides I (mainly C=O stretching) and II (mainly N-
H bending) and III (mainly C-N stretching and N-H bending)
groups of proteins (Figure S4, see I and II red line) that usually
correspond to the organic matrix (90% type I collagen) in bone
(Figure S4, see Blue and black line). No phosphate or
carbonate molecular vibrations were found, indicating the
absence of mineral within the PC3c tumor in vivo (Figure S4).
On the other side, new bone matrix obtained from mice tibia
injected with PC3c cells showed the presence of mineral
(Figure S4). Concomitantly to these result, high amount of
Type I Collagen was found to be expressed by PC3c when
compared with PC3 cells by real-time PCR in vitro (Figure 5A).
Additionally, PC3c cells were shown surrounded by typical type
I Collagen fibers in situ as judged by electron microscopy
(Figure 5B see arrows and higher magnification). All together,
these data suggest higher osteomimicry properties for PC3c
compared with PC3 cells, thereby explaining at least in part,
Table 1. Histomorphometric analysis of tibia with
metastases induced by injection of PC3 and PC3c cells.
 BV/TV (%) TB/STV (%)
Sham (n=10) 22,4 +/- 2,9 0
PC3 (n=6) 3,6 +/- 4,1*** 72,6 +/- 6,6***
PC3c (n=8) 39,5 +/- 3,0*$ 36,6 +/- 4,5***$
BV/TV: bone volume/ total volume. TB/STV: tumor burden/soft tissue volume.
Sham were performed as control. n is the number of legs with bone metastases.
*P<0,05; ***P<0,001 compared with Sham; $P<0,001 compared with PC3.
doi: 10.1371/journal.pone.0075092.t001
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their capacity to induce mixed osteoblastic/osteolytic bone
lesions.
Discussion
In this study, we have established and characterized a new
androgen-independent prostate cancer cell line (PC3c) which
rapidly gives mixed bone lesions in male SCID mice, 10 weeks
Figure 2.  Induction of lytic and mixed bone lesions by PC3 and PC3c cells respectively after intratibial injection.  (A) PC3
and PC3c cells were inoculated into male SCID mice; 10 weeks post inoculation, radiography revealed pure osteolytic lesions in
mice injected with PC3 cells (n=6) (E) and mixed lesions in mice injected with PC3c cells (n=8) (I) compared to mice injected with
PBS (n=10) (A) (see *(lysis) and white arrows (formation)). (B,C- F,G-J,K) Three-dimensional micro-CT reconstructions of tibiae and
(D, H, L) histology after Goldner’s Trichrome staining confirmed the radiography results. T: Tumor; NB: New Bone.
doi: 10.1371/journal.pone.0075092.g002
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Figure 3.  Stimulation of osteoclasts and osteoblasts by PC3c cells in vitro.  (A) Primary mouse bone marrow cells were
cultured in the presence of RANKL and M-CSF and treated or not (Ct) with conditioned medium obtained from PC3 and PC3c cells.
More OCs (white arrow) were formed in cultures treated with PC3c conditioned medium compared to cultures treated with PC3
conditioned medium and Ct (ANOVA, p<0.0001). (B) Primary mouse calvaria cell cultures were treated from day 1-21 with
conditioned medium obtained from PC3 and PC3c cell. Mineralized bone nodules were present and visualized by von Kossa
staining at day 21 (see mineral in black, white arrows). Mineralized bone nodule formation was decreased when primary cells were
treated with conditioned medium from any of the PC3/PC3c cells (compared with non-treated (Ct) cells); the decrease was less
when PC3c cell conditioned medium was used (compared with PC3) (ANOVA, p<0.001 versus Ct and versus PC3). (C) PC3
conditioned media stimulated the expression of OPG and RANKL in primary OBs compared with non-treated (Ct) while PC3c
conditioned media only inhibits the expression of OPG compared with Ct leading to an higher RANKL/OPG ratio in PC3c conditions.
(D) Detection by real-time PCR of SOST, DMP1, OPG and RANKL mRNA expression in MLO-Y4 cells treated with PC3 and PC3c
conditioned medium. Results are plotted as the mean number of OC ± SD and OB nodules ± SD of three wells for controls and each
condition and are representative of two independent experiments. Genes expression was assessed by real-time PCR on triplicate
samples and normalized against that of the ribosomal protein gene L32 *p<0.05; **p<0,001, ***p<0,0001.
doi: 10.1371/journal.pone.0075092.g003
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Figure 4.  PC3c cells osteomimicry properties.  (A) Immunodetection of OPN in OB in bone metastases induced by PC3c cells
(see OBs a and b magnifications of a; see black arrows) (A) and in tumors cells (B a). Similarly to OPN, BSP expression is detected
in tumors cells in vivo (B, b). (C) Similarly to primary mouse calvaria cells, PC3 and PC3c were cultured in osteogenic conditions for
21 days. ALP (a, c) and von Kossa staining (b, d) show high expression of ALP (c) and mineralization (white arrow) (d) in PC3c cells
while no ALP expression (a) and mineralization were detected in PC3 cells (b). (D) Detection by real-time PCR of OPN, ALP and
OCN mRNA expression in PC3c and PC3 cells cultured in osteogenic conditions for 21 days. Gene expression was assessed by
real-time PCR on triplicate samples and normalized against that of the ribosomal protein gene L32 **p<0,001. Bar=200µm T:
Tumor; OB: osteoblasts; NB: New Bone.
doi: 10.1371/journal.pone.0075092.g004
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after intra-tibial tumor cells injection. This model may be useful
to study cellular and molecular mechanisms that differ between
androgen-dependent and androgen-independent prostate
carcinomas when they metastasize to bone. In prostate cancer,
androgen blockade strategies are usually used to treat
osteoblastic bone metastases. However, responses to these
therapies are often brief due to post-traductional modifications
or mutations of AR that reduce ligand binding and inevitably
lead to CRPC [26,27]. The role of AR pathway in the
osteoblastic progression of prostate cancer is poorly
understood because available models of mixed and pure
osteoblastic lesions (C4-2B, PCa2B, VCaP) are mainly
androgen responsive like [28,29]. Consequently, an active AR
pathway is believed to be implicated in the osteoblastic
progression of prostate cancer. However, concerning our PC3c
model, this assumption does not occur as both cells lines PC3
and PC3c cell lines do not express AR. On the other side, AR
negative models commonly used as PC3 and DU145 cells that
derived from CRPC patients induced pure osteolytic lesions
and do not reproduce what it is observed in clinic [30,31]. Then,
in order to meet the need for clinically relevant models of
prostate cancer-associated bone lesions, more recent
hormone-independent models have been developed like MDA
PCa 118 and Ace-1 that similarly to the PC3c model do not
express AR and induce mixed lesions [22,32]. Nevertheless,
osteogenesis that was induced by FGF-9 in the MDA PCa 118
model was not implicated in the osteoblastic response induced
by PC3c as FGF-9 expression was not statistically significantly
modulated between PC3 and PC3c cells.
Interestingly, when compared with PC3, PC3c cells highly
expressed ET-1, a mitogenic factor for OB [33,34]. ET-1 is
known to contribute to osteoblastic progression of prostate
cancer cells by stimulating OB proliferation through the
negative regulation of the inhibitor of the Wnt signaling, DKK1
which may explain, at least in part, the decrease of DKK1
observed in PC3c cells [35]. Moreover, a decrease of DKK1
serum level in patients with advanced prostate cancer has
been reported to be associated with occurrence of osteoblastic
lesions which suggests that DKK1 inhibition in PC3c cells may
contribute to the osteoblastic phenotype induced by these cells
[12]. BMPs have also been implicated in the formation of new
bone induced by prostate cancer and the inhibition of BMPs by
their inhibitor Noggin in C4-2B cells induces a decrease in the
osteoblastic response, suggesting that the low expression level
of Noggin in PC3c cells compared with PC3 cells may also
contribute to the osteoblastic lesions induced by PC3c cells
[4,10]. Finally the over-expression of OPG may also contribute
to the osteoblastic response induced by PC3c cells by limiting
Figure 5.  PC3c cells highly expressed type I collagen.  (A) Detection by real-time PCR of type I collagen mRNA expression in
PC3c and PC3 cells cultured in normal conditions. Gene expression was assessed by real-time PCR on triplicate samples and
normalized against that of the ribosomal protein gene L32 *p<0,05. (B) Visualization of type I collagen in PC3c cells cultured on
glass coverslip by electron microscopy (see black arrows).
doi: 10.1371/journal.pone.0075092.g005
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OC differentiation. Based on OC and OB in vitro assay and
TRAP staining in vivo, it appears that PC3c cells can also over
stimulate osteoclastogenesis directly by acting on OC
precursors and indirectly by increasing the RANKL/OPG ratio
by OBs conducting to a general bone remodeling stimulation.
On the other side, the RANKL/OPG ratio was not modulated by
osteocytes like MLO-Y4 cells. Concerning osteocyte
involvement into prostate cancer progression in bone, we found
that the expression of SOST, an inhibitor of Wnt signaling, was
induced by PC3 cells conditioned medium, suggesting a direct
effect of osteocytes on OB differentiation during tumor bone
progression. Meanwhile the expression of DMP1, a member of
the small integrin-binding ligand N-linked glycoproteins
(SIBLINGs) that is involved in phosphatemia regulation, was
only stimulated by PC3c cells conditioned media which,
combined with the expression of type I collagen by the tumor
cells, may contribute to the formation of the new bone
mineralized matrix observed in vivo and by infrared
microspectroscopy [36,37].
Finally, PC3c cells had strong osteomimicry properties
compared to PC3 cells, as judged by the expression of bone-
associated markers such as OPN, BSP, Runx2, and type I
collagen and by the ability of this cell line to form calcified
matrix under osteogenic conditions, while PC3 are negative for
both. Bone matrix proteins are also known to influence tumor
localization in the skeleton and the phenotype of skeletal
lesions. For example, OPN and BSP have been associated
with breast and prostate cancer cells affinity for bone, migration
and survival [38]. Moreover, differential expression of BSP and
OPN has been shown to be implicated in the switch between
osteolytic versus osteoblastic bone lesions. Indeed, strong BSP
expression has been found mainly in prostate when compared
with breast cancer lesions while high level of OPN was
essentially shown in breast versus prostate cancer. Thus,
associating BSP to sclerotic lesions as a stimulator of bone
mineralization and OPN to osteolytic bone lesions as an
activator of OC [39]. Differences into OPN expression level
between PC3 and PC3c cells under normal conditions cannot
explain the osteoblastic pattern observed in PC3c model and it
is likely that OPN and BSP contribute to the osteomimicry
properties of PC3c cells by promoting cell attachment and bone
matrix mineralization, respectively. Additionally, type I collagen
and ALP may also be part of this osteosclerotic pattern induced
by PC3c cells by being involved in the new bone matrix
formation and mineralization respectively.
In summary, we have established a new AR-negative
prostate cancer cell line that is derived from PC3 cells and that
recapitulates the osteoblastic phenotype of prostate cancer in
bone. This new model may be helpful for the identification of
new signaling pathways that are involved in the progression of
prostate cancer in bone and may provide a valuable tool for
investigating the mechanisms of androgen-independent
prostate cancer cells osteomimicry in osteoblastic bone
lesions. Finally, it can also provide a clinically relevant
experimental model for testing the effects of new treatments for
bone metastases.
Supporting Information
Figure S1.  Epithelial phenotype of PC3c cells. Detection by
real-time PCR of E-Cadherin, N-Cadherin and vimentin mRNA
expression in PC3 and PC3c cancer cells lines. Genes
expression was assessed by real-time PCR on triplicate
samples and normalized against that of the ribosomal protein
gene L32 **p<0,001, ***p<0,0001.
(TIF)
Figure S2.  ET-1 and OPG expression by PC3c cells in
vivo. Immunostaining for ET-1 (A, B) and OPG (C, D) is higher
in bone metastases induced by PC3c cells (B, D) compared to
PC3 cells (A, C). Bar=200µm T: Tumor.
(TIF)
Figure S3.  Visualization of TRAP positive OC in bone
metastases induced by PC3 and PC3c cells. TRAP (red)
staining of OCs (black arrow) realized in sections of tibiae
taken from mice injected with Sham (A), PC3 (B) and PC3c
cells (C). Bar=200µm T: Tumor.
(TIF)
Figure S4.  Identification of amide groups in PC3c
subcutaneous tumors. (A) IR spectra obtained on PC3c
tumors (red curve), on cortical tibial bone matrix bone from
Sham (Black curve) or PC3c mice (Blue curve) illustrates the
presence of amide I and II and III groups usually corresponding
to organic matrix (mainly to type I collagen) observed in bone
matrix. As expected, mineral was shown by IR on bone matrix
of tibia injected by PBS (Sham) (Black curve) or PC3c cells
(Blue curve) (see peaks corresponding to ν3PO4, ν2CO3 and
ν4PO4 groups) while it was not present in PC3c tumors (red
curve; see ν3PO4, ν2CO3 and ν4PO4 groups). (B) Bone quality
analysis performed by infrared microspectroscopy. No
differences were observed between normal cortical bone and
the new bone (NB) induced by PC3c tumor cells (n=2).
(TIF)
Table S1.  Mouse primers and using conditions.
(DOC)
Table S2.  Human primers and using conditions.
(DOC)
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